Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Corporate

07 March 2023

GenSight Biologics Provides Update on LUMEVOQ® Manufacturing and Commercialization Timelines

28 February 2023

Rare Disease Day 2023: GenSight Biologics Raises Awareness of Leber Hereditary Optic Neuropathy (LHON)

04 January 2023

GenSight Biologics to Present at Upcoming Investor Conferences

04 November 2022

GenSight Biologics secures a €35 million credit facility from the European Investment Bank to support the launch of LUMEVOQ® in Europe

20 September 2022

GenSight Biologics to Present at Upcoming Industry and Investor Conferences

19 September 2022

GenSight Biologics Announces Successful Completion of LUMEVOQ® Engineering Batch Validating Implemented Corrective Actions

12 September 2022

GenSight Biologics strengthens its management team to support the launch of LUMEVOQ® in Europe

16 June 2022

GenSight Biologics Announces Participation and Presentation of GS010 Clinical Data at EUNOS 2022

29 April 2022

GenSight Biologics Announces the Filing of its 2021 Universal Registration Document

25 Oct 2021 - 28 Oct 2021

BIO-Europe 2021, Virtual

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 14
  • View next 9 articles
© 2023 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page